Sigma Halts Boots Acquisition
Sigma Healthcare Withdraws from $14 Billion Boots UK Acquisition Due to Strategic Objectives
Key Points
Sigma said it exited the Boots process “just five days after” it had confirmed to the ASX that it was at the table, highlighting how quickly preliminary diligence led to a stop.
The abandoned proposal was for a roughly $14 billion acquisition of the UK’s largest pharmacy chain, described by Sigma as an “1800-store retailer.”
In its explanation to investors, Sigma reiterated that “International growth is one of Sigma’s four key strategic growth pillars,” adding it would continue “driving growth in its core offshore markets” while “assessing and seeding new markets.”
Bloomberg reported Sigma’s formal wording to the market: it “has elected to withdraw its interest and cease discussions immediately.”
Sigma Healthcare pulled out of the race to buy UK pharmacy giant Boots just five days after confirming it was in the running. The Australian company said the roughly A$14 billion deal — which would have handed it control of an 1,800-store chain — would not meet its "strategic and capital investment objectives," according to ASX Release.
Sigma's shares surged as much as 8% to around A$2.85 on the news, according to Reuters. Investors read the exit as a win. The stock had fallen 5.5% just days earlier when the company first confirmed it was in talks.
A $14 Billion Deal That Lasted Five Days
The sale process was set in motion by Sycamore Partners, the New York private equity firm that bought Walgreens Boots Alliance for $23.7 billion in 2025 and then carved out Boots as a standalone business, according to Financial Times. Sigma confirmed to the Australian Securities Exchange on June 10 that it was in "preliminary discussions." Five days later, it was out.
Sigma's board said it "engaged in the Boots sale process given the potentially unique opportunity it presented" but ultimately concluded the deal did not stack up. The Guardian reported the company's formal exit statement: it "has elected to withdraw its interest and cease discussions immediately."
Funding Gap and Integration Risk Spooked Investors
Analysts at Macquarie said a Boots deal would have needed a "sizeable" equity raise to cover the $10 billion USD price tag, according to Motley Fool Australia. That would have diluted existing shareholders significantly. Sigma had just completed an A$8.8 billion reverse merger with Chemist Warehouse in February 2025 — its balance sheet had little room for another giant bet.
Marc Jocum, a senior strategist at Global X ETFs, said "investors appear to have breathed a sigh of relief," according to The Guardian. The rally showed the market wanted management focused on "opportunities already in front of them" — namely, finishing the Chemist Warehouse integration at home.
Sigma Keeps a Smaller UK Foothold Through Greenlight Deal
Sigma is not walking away from Britain entirely. In May 2026, it signed a memorandum of understanding with Greenlight Healthcare, an employee-owned UK pharmacy group. The deal gives Sigma a 75% stake in 22 community pharmacies, according to The Pharmaceutical Journal. The plan is to rebrand those stores under the Chemist Warehouse name, with a first pilot site on Hoxton Street in northeast London.
The strategy is a slow burn rather than a blitz. International sales for Chemist Warehouse rose 24.7% year-to-date in 2026, per Motley Fool Australia. Sigma said it will keep "driving growth in its core offshore markets" while "assessing and seeding new markets" — language that points to organic growth over a blockbuster acquisition.
Boots Now Waits on the Weston Family or a London IPO
With Sigma gone, the Weston family — the Canadian billionaires behind Loblaw and Shoppers Drug Mart — are now the primary strategic suitor for Boots, according to The Guardian. Boots employs around 51,000 people across its roughly 1,800 UK stores. A deal with the Westons would be a private exit for Sycamore Partners.
If those talks fail, Sycamore may have to turn to a London IPO instead, according to au.marketscreener.com. That outcome would be welcomed by the London Stock Exchange, which has struggled to attract major new listings in recent years. For now, Boots' future remains unresolved.
Sentiment
Mostly PositivePublishers
17
Articles
87
Reach
104
